Anavex Life Sciences (AVXL) Cash from Operations Growth (5y) (2015 - 2025)
Anavex Life Sciences (AVXL) Cash from Operations Growth (5y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Anavex Life Sciences | 223.91 Mn | 92.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.90% |
| Sep 30, 2025 | -6.59% |
| Jun 30, 2025 | -25.25% |
| Mar 31, 2025 | -2.16% |
| Dec 31, 2024 | -16.18% |
| Sep 30, 2024 | -21.31% |
| Jun 30, 2024 | 7.14% |
| Mar 31, 2024 | -21.89% |
| Dec 31, 2023 | -11.96% |
| Sep 30, 2023 | -7.61% |
| Jun 30, 2023 | -29.66% |
| Mar 31, 2023 | -24.65% |
| Dec 31, 2022 | -9.86% |
| Sep 30, 2022 | -13.03% |
| Jun 30, 2022 | -18.85% |
| Mar 31, 2022 | -69.07% |
| Dec 31, 2021 | -2.11% |
| Sep 30, 2021 | -32.73% |
| Jun 30, 2021 | -27.60% |
| Mar 31, 2021 | -30.92% |